He-Yi She Ye

Oneness Biotech is a leading Taiwanese biopharmaceutical company dedicated to the development of innovative therapies for metabolic diseases, chronic inflammation, and cancer. The company's flagship product, Fespixon (ON101), is a first-in-class botanical drug approved in multiple regions for the treatment of diabetic foot ulcers, addressing a significant unmet need in wound care. Oneness also possesses a diverse pipeline, including FB825, a monoclonal antibody for atopic dermatitis and asthma that was licensed to LEO Pharma in a record-breaking deal for the Taiwan biotech industry. Additionally, the company is advancing SNS812, an siRNA-based treatment for COVID-19, leveraging its proprietary nucleic acid drug platform. With a focus on global commercialization and advanced manufacturing, Oneness Biotech aims to provide transformative healthcare solutions through its unique macrophage regulation and antibody technologies.